Abstracts tagged "Allopurinol"

Abstract Number: 1113 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Probenecid Versus Allopurinol: A Population-Based Cohort Study
Seoyoung C. Kim¹, Tuhina Neogi², Eun Ha Kang³, Jun Liu⁴, Rishi J. Desai⁵, MaryAnn Zhang⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Gout is associated with an increased risk of cardiovascular (CV) disease including myocardial infarction (MI), stroke and heart failure (HF). Although both probenecid and…
Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting
Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
Douglas C.A. Taylor¹, An-Chen Fu¹ and Robert Morlock², ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 1137 • 2017 ACR/ARHP Annual Meeting
Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol
Thomas Bardin^1,2,3, Quang Nguyen Dinh¹, Khoi Tran Minh¹, Nghia Le Hieu¹, Minh Do Duc⁴, Pascal Richette^5,6 and Matthieu Resche-Rigon^3,7, ¹French-Vietnamese Gout Research Center, Ho Chi Minh City, Viet Nam, ²Rheumatology, Hôpital Lariboisière, Paris, France, ³Université Paris Diderot, Paris, France, ⁴Molecular Biology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam, ⁵Rhumatologie, Hôpital Lariboisière, Paris, France, ⁶Rheumatology Department, Université Paris Diderot, Paris, France, ⁷Biostatistics, Hôpital Saint-Louis, Paris, France
Background/Purpose: Gout is frequent and severe in Vietnam, where urate-lowering drugs (ULD) are seldom used and many patients are treated only with traditional herbal medicine.…
Abstract Number: 1144 • 2017 ACR/ARHP Annual Meeting
Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Yu Guo⁴, Stuart Katz⁵, Binita Shah⁵, Irina Dektiarev⁵, Svetlana Krasnokutsky Samuels² and Michael Pillinger², ¹Medicine, Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, New York University School of Medicine, New York, NY, ³Medicine/Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁴Population Health/Statistics, New York University School of Medicine, New York, NY, ⁵Medicine/Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: We have previously reported that patients with gout have impaired vascular endothelial and smooth muscle responsiveness, but whether initiating appropriate gout therapy ameliorates these…
Abstract Number: 2058 • 2017 ACR/ARHP Annual Meeting
A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound
Percy Balderia and Elizabeth R. Wahl, Rheumatology, University of Washington School of Medicine, Seattle, WA
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend use of either allopurinol or febuxostat as first-line approaches to urate lowering therapy in gout. Prior studies…
Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
Abstract Number: 2265 • 2017 ACR/ARHP Annual Meeting
Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Roshanak Habibi¹, David T Liss², Sreelakshmi Panginikkod¹, Alvaro Altamirano Ufion³, Ehsan Rajabirostami¹ and Manish Jain⁴, ¹Internal Medicine, Presence Saint Francis Hospital, Evanston, IL, ²Northwestern University, Chicago, IL, ³Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, ⁴Rheumatology, Presence Saint Francis Hospital, Evanston, IL
Background/Purpose: The increasing global burden of gout disease and its impact on the patient’s quality of life calls for new strategies in management. Even though…
Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
MaryAnn Zhang¹, Jun Liu², Eun Ha Kang³, Rishi J. Desai⁴, Tuhina Neogi⁵, Daniel H. Solomon¹ and Seoyoung C. Kim¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…
Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Ted R. Mikuls¹, TC Cheetham², Gerald D. Levy³, Nazia Rashid⁴, Kimberly Low⁵, Brian W Coburn⁶, Kenneth Saag⁷, Lang Chen⁸ and Jeffrey R. Curtis⁹, ¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ³Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, ⁵Kaiser Permanente Southern California, Panorama City, CA, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
Abstract Number: 1957 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Chronic Kidney Disease with Allopurinol Use
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Yuqing Zhang³ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Chronic kidney disease (CKD) is a cause and consequence of hyperuricemia. While clinicians are often cautious about using allopurinol in patients with CKD, there…
Abstract Number: 2160 • 2016 ACR/ARHP Annual Meeting
Allopurinol Use and the Risk of Acute Cardiovascular Events in Patients with Gout and Diabetes
Jasvinder A. Singh¹, Rekha Ramachandaran² and Jeffrey Curtis³, ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To examine the effect of allopurinol on the risk of incident myocardial infarction (MI) or stroke in patients with gout and diabetes Methods: We…
Abstract Number: 2956 • 2016 ACR/ARHP Annual Meeting
Optimization of Thiopurines with a Xanthine Oxidase Inhibitor in Patients with Autoimmune Systemic Diseases
Mériem Belhocine¹, Aurélie Chapdelaine¹, Maxime Doré², Yves Troyanov³ and Anne-Marie Mansour¹, ¹medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ²Pharmacy, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ³Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada
Background/Purpose: Thiopurines are a mainstay for the treatment of autoimmune diseases. However, in inflammatory bowel diseases (IBD), 14-18 % of patients manifest a skewed metabolism…
Abstract Number: 3128 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Dual Energy Computed Tomography Study on the Effect of Urate Lowering Therapies on the Reduction of Tophus Burden in Patients with Chronic Gout
Hanna Ellmann¹, Sara Bayat¹, Isabelle Oliveira¹, Matthias Englbrecht^2,3, Elizabeth Araujo⁴, Alexander Cavallaro⁵, Silvana Mendonca⁶, Michael Lell⁵, Bernhard Manger², Georg Schett⁷ and Juergen Rech⁷, ¹Medical Department 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3; Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁵Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁶Americas Medical City, Rio de Janeiro, Brazil, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Dual energy computed tomography (DECT) allows reliably detecting and quantifying tophus burden in patients with chronic gout. Longitudinal studies on the effect of uric…
Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Jesse Hall¹, Michael Gillen², Xiaojuan Yang¹, Sha Liu¹, Susan Walker¹, Vicki Clauson¹ and Martin Kankam³, ¹Ardea Biosciences, Inc., San Diego, CA, ²AstraZeneca, Gaithersburg, MD, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…